February 2026
Beyond Corticosteroids: Novel Therapeutics for Refractory ITP and wAIHA
David J. Kuter, MD, DPhil, and Sandhya R. Panch, MD, MPH
Learning Objectives
1. Describe the pathogenesis of immune-mediated cytopenias, including immune thrombocytopenia (ITP) and warm autoimmune hemolytic anemia (wAIHA) to enhance the identification and understanding of these conditions.
2. Understand and implement current corticosteroid-sparing approaches to improve efficacy, patient safety, and quality of life.
3. Apply clinical data and mechanisms of action of new and emerging therapies to tailor treatment strategies in autoimmune cytopenias.
4. Increase clinician confidence in integrating new and emerging therapies into practice.
Activity Disclosures
This educational activity is supported by an independent medical educational grant from Sanofi.
This Wiley developed grant-funded resource provides ASH Clinical News readers with convenient access to information that may be of interest. It should not be considered an ASH endorsement or recommendation of the grantor’s products, services, policies, or procedures. ASH Clinical News editors were not involved in the development of this content.
Disclaimer
David J. Kuter
Research: Fulcrum, Novartis, Principia, Sanofi, Takeda
Consulting: Alexion, Alpine, Amgen, argenx, BioCryst, Blackstone, Bristol Myers Squibb, Cardurion, Caremark, Chugai, Cyrus, Hengrui, Hutchmed, Iconic Bio, Immunovant, Inmagenebio, Kaigen, Kyowa-Kirin, Lilly, Medscape, Merck Sharp Dohme, New York Blood Center, Nexcella, Novartis, Nurix, Nuvig, Ouro, Peerview, PER, Pfizer, Platelet Disorder Support Association, Principia, Regeneron, Rigel, Sanofi, Seismic, Sobi, Takeda, Timberlyne, UCB, Up-To-Date, Vertex, Verve.
Sandhya R. Panch
Consulting: Johnson and Johnson, Recordati Rare Diseases Inc., Sanofi
This activity underwent review in line with standards of editorial integrity and publication ethics. Potential conflicts of interest have been identified and resolved in accordance with John Wiley and Sons, Inc.’s Policy on Activity Disclosure and Conflict of Interest. The primary resolution method was review by an unconflicted expert. For information about the accreditation of this program, please contact [email protected].
Accreditation
John Wiley & Sons, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
John Wiley and Sons, Inc. designates this enduring CME activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity. For information on applicability and acceptance of continuing medical education credit for this activity, please consult your professional licensing board.
This activity is designed to be completed within 1 hour and complete the activity during the valid credit period, which is up to three years from initial publication. Additionally, up to 3 attempts and a score of 70% or higher is needed to pass the post-test and claim credit. You will need to log into your Wiley Health Learning account (registration is free) to complete this activity and earn a certificate.
To begin, please click the Pre-test button below to contribute to our outcomes data then proceed to the course content.
